



For Immediate Release • July, 30 2024

Proesis Bio Earns FDA Approval for Second Plasma Collection Facility

*FDA Approval Highlights Proesis Bio's Commitment
to Expanding Plasma Collection Operations*

Boise, ID -- Tuesday, July 30, 2024 -- Proesis Bio, a leading innovator in the plasma industry, announced that it has received U.S. Food and Drug Administration (FDA) approval for its second plasma collection facility. This facility is located in Raleigh, North Carolina. This state-of-the-art facility commenced operations in October of 2023 and with the FDA approval, it is now licensed to introduce human source plasma into interstate commerce for further manufacturing in the U.S.

"The approval of our Raleigh center represents a key milestone in our strategic growth plan," said Kris Jonas, CEO of Proesis Bio. "This achievement is a testament to our team's dedication to expanding our plasma collection network and enhancing our ability to meet the growing demand for plasma-derived therapies. We extend our gratitude to the FDA for their thorough and timely review of this supplement to our existing Biologics License."

Proesis Bio's new facility features advanced services to optimize the donation process and ensure donor comfort. The center offers an elegant reception area, improved donor experiences via the ProesisPlus™ app, free Wi-Fi, and highly trained staff dedicated to providing a safe and pleasant donation experience. At full capacity, the center expects to employ 30 healthcare professionals, all trained to prioritize donor safety and comfort.

"We are proud of our team's hard work and commitment to making this approval possible," added Jonas. "The Raleigh center will play a crucial role in supporting our mission to provide high-quality plasma for life-saving therapies, and it positions us to better serve both our donors and patients."

To learn more about the Proesis Bio donation process and to schedule an appointment, please visit: www.ProesisBio.com or visit in person at 10441 Moncreiffe Rd, Raleigh, NC 27617.

Making a Difference in the Industry

Proesis Bio was established in 2022 and is comprised of a group of highly experienced individuals from the plasma industry. Their primary objective is to foster opportunities that boost the availability of source plasma, a crucial component in producing plasma-derived therapies used to treat rare and chronic diseases. For more information and a list of centers, please visit www.ProesisBio.com.

Proesis Bio and ProesisPlus™ are registered trademarks of Proesis Bio in the United States. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

For Press Inquiries:
Gabby Weeks
gabby.weeks@proesisbio.com

For More Information on ProesisPlus™, visit: www.ProesisBio.com.